Regorafenib (BAY 73-4506, Stivarga®, Bayer, Leverkusen, Germany) is another oral tumor deactivation agent that potently blocks multiple protein kinases, including those involved in tumor angiogenesis (VEGFR receptor 1, −2, −3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), metastasis (VEGF receptor 3, PDGFR, FGFR), and tumor immunity (CSF1R). This evidence concerns the gene BRAF and neoplasm.